Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813Phase 2Recruiting
- Sponsor
- Apollo Therapeutics
- Start
- May 2026
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of camoteskimab in atopic dermatitis (AD), sponsored by Apollo Therapeutics. Started May 2026; status: recruiting.
02
Drugs
camoteskimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07599813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07599813.